Dendreon (DNDN) fell a heartbreaking 62% in AH trading after its earnings report  showed weak...


Dendreon (DNDN) fell a heartbreaking 62% in AH trading after its earnings report  showed weak sales of cancer drug Provenge, prompting the firm to abandon its sales guidance and cut jobs. Annual sales of Provenge, Dendreon's only marketed product, will likely be closer to $200M than the $350M-400M previously projected.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs